SCHEMBL2324765

SCHEMBL2324765

CCOP(=O)(O)CC(=O)c1cc(Cl)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
ALDH1A1 P00352 5/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 1/20 0.47
ERCC5 P28715 1/20 0.47
FEN1 P39748 1/20 0.47
TDP1 Q9NUW8 3/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
NR1I2 O75469 1/20 0.44
TP53 P04637 3/20 0.44
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322162 0.89 KMT2A (0.53) ALDH1A1MAPTERCC5FEN1TDP1
SCHEMBL2329637 0.84 TDP1 (0.43) ALDH1A1LMNAMAPTTDP1KMT2A
SCHEMBL1549852 0.83 HTT (0.41) LMNAMAPTTDP1KMT2AMEN1
SCHEMBL2322233 0.82 ERCC5 (0.44) ALDH1A1LMNAMAPTERCC5FEN1
SCHEMBL2322050 0.80 POLB (0.43) ALDH1A1LMNAMAPTTDP1KMT2A
SCHEMBL1549681 0.78 KMT2A (0.42) TDP1KMT2AMEN1NR1I2HPGD
SCHEMBL2324762 0.78 ALDH1A1 (0.50) TAS1R3TAS1R1ALDH1A1LMNAMAPT
SCHEMBL2324686 0.77 TAS1R3 (0.47) TAS1R3TAS1R1LMNAMAPTERCC5
SCHEMBL2328992 0.75 NPC1 (0.40) TAS1R3TAS1R1ALDH1A1LMNAMAPT
SCHEMBL16770754 0.74 ERCC5 (0.61) TAS1R3TAS1R1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 TAS1R3 3044/4885TAS1R1 1712/4885ALDH1A1 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.